MDI Therapeutics is developing a first-in-class orally available inhibitor of plasminogen activator inhibitor-1 (PAI-1) to treat fibrosis and fibroproliferative diseases. This approach targets the pathological processes associated with chronic fibrotic conditions, aiming to improve patient outcomes through enhanced regulation of fibrinolysis and tissue repair mechanisms.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Fibrosis and fibroproliferative diseases lead to significant morbidity and mortality due to excessive tissue scarring and organ dysfunction. Current treatment options are limited, and there are no approved drugs that directly inhibit plasminogen activator inhibitor-1 (PAI-1), a key regulator of pro-inflammatory and pro-fibrotic processes. The inherent structural instability of PAI-1 has historically posed challenges in developing effective and specific inhibitors.
Solution
MDI Therapeutics is developing a first-in-class, orally available small molecule inhibitor of PAI-1, addressing the underlying pathology of chronic fibrotic conditions. Their lead program, MDI-2517, aims to restore the balance of fibrinolysis and promote tissue repair by selectively targeting and inhibiting PAI-1. This approach modulates cellular adhesion, migration, and proliferation, offering a novel therapeutic strategy for diseases characterized by excessive fibrosis. MDI-2517 is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
Target Audience
The primary target audience includes patients suffering from fibrosis and fibroproliferative diseases, as well as physicians specializing in pulmonology, rheumatology, and other fields managing fibrotic conditions.
Features
- Orally available small molecule PAI-1 inhibitor
- First-in-class therapeutic approach directly targeting PAI-1
- Designed to selectively inhibit PAI-1, minimizing off-target effects
- Aims to restore fibrinolysis and promote tissue repair
- Currently in Phase 1 clinical trials